哌拉西林钠及哌拉西林钠-他唑巴坦对肠杆菌的体外抗菌作用

目的调查哌拉西林钠与哌拉西林钠-他唑巴坦对肠杆菌的体外抗菌作用。方法选择我院2011年1月—2013年6月临床送检标本29 539份,对其中检出的肠杆菌属大肠埃希菌、肺炎克雷伯菌及其对哌拉西林钠及哌拉西林钠-他唑巴坦的耐药情况进行分析。结果我院近3年间共检出肺炎克雷伯菌495株,大肠埃希菌389株。与哌拉西林钠比较,近3年间肺炎克雷伯菌、大肠埃希菌对哌拉西林钠-他唑巴坦药物敏感率均较高,差异均有统计学意义(P0.05);但近3年间肺炎克雷伯菌、大肠埃希菌对上述2种药物的敏感率均呈下降趋势。结论他唑巴坦可增强哌拉西林钠的抗菌活性,抗生素治疗应根据药敏结果并结合其耐药特点选择具有协同作用的不同类型抗生素,以减少院内感染。

Antimicrobial Activity of Piperacillin and Piperacillin-tazobactam against Enterobacteria in Vitro

Objective To investigate antimicrobial activity of Piperacillin and Piperacillin-tazobactam against enter- obaeteria in vitro. Methods Detection rates of escherichia coli and klebsiella pneumoniae in 29 539 clinical specimens dur- ing January 2011 and June 2013, and their resistance status against Piperacillin and Piperacillin-tazobactam were respectively analyzed. Results A total of 495 strains of klebsiella pneumoniae and 389 strains of escherichia eoli were detected. When compared with that of Piperacillin, the sensitive rates of klebsiella pneumoniae and escherichia coli against Piperacillin- tazobactam were higher in the last 3 years, and the differences were statistically significant （P 〈 0.05） ; however, the sensi- tive rates of two bacteria to Piperacillin and Piperacillin-tazobactam showed downward trend in the last 3 years. Conclusion Tazobactam may enhance antibacterial activity of Piperacillin. However, for the sake of reducing nosocomial infection rate, Antibiotics therapy should choose synergistic drug combinations according to result of antibiotics susceptibility testing combined with resistance characteristics.